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Abstract
VIM-producing Klebsiella pneumoniae (VPKP) has been identiﬁed as a source of hospital outbreaks and is prevalent particularly in the
Mediterranean region. In this study we have characterized eight VPKP isolates identiﬁed in Scandinavia during 2005–2008. With the
exception of one isolate, all were from patients with recent history of hospitalization abroad (Greece, n = 6; Turkey, n = 1). Multilocus
sequence typing (MLST) resulted in ﬁve sequence types (STs), ST36 (n = 1), ST147 (n = 4), ST272 (n = 1), ST273 (n = 1) and ST383
(n = 1), which except for ST272 were part of putative international clonal complexes. All were multidrug resistant due to the presence
of other resistance determinants, including extended-spectrum b-lactamases (CTX-M-3, SHV-5 and SHV-12), 16S rRNA methylases
(ArmA) and plasmid-mediated quinolone resistance determinants (QnrS). One isolate harboured a novel VIM-variant (VIM-26) while
VIM-1 and VIM-19 were detected in six and one isolate, respectively. Two different genetic structures surrounding the blaVIM gene were
identiﬁed in four isolates. In two isolates blaVIM-1 and blaVIM-26 were located in an integron similar to In-e541 (intI1;blaVIM-1/-26;aacA7;
dhfrI;aadA1;3¢CS) while in the other two isolates blaVIM-1 was located in an integron lacking 3¢CS but with an IS26 element in the 3¢end
(intI1;blaVIM-1;aac(6¢)-Ib;IS26), as identiﬁed in the IncN plasmid pKOX105. The blaVIM-genes were located on transferable plasmids ranging
from 40 to 240 kb and associated with Tn21 in four isolates. PCR-based replicon typing indicated association of blaVIM with IncN
(n = 3) and A/C (n = 1) broad-host-range plasmids but also with unknown replicons (n = 4). In conclusion, Scandinavian VPKP is associ-
ated with importation and genetically related to international clones encoding transferable plasmid-mediated multidrug resistance.
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Introduction
The increased prevalence of acquired carbapenem-hydroly-
sing b-lactamases in Gram-negative bacteria is of great
concern due to their ability to hydrolyse virtually all b-lac-
tam antibiotics, as well as their genetic association with
transferable multidrug resistance [1]. As a consequence,
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infections with carbapenemase-producing bacteria have
become a serious challenge for infection control and antibiotic
therapy. Acquired metallo-b-lactamases (MBLs) are a diverse
family of carbapenemases [1]. Among Klebsiella pneumoniae the
VIM-group and particularly VIM-1 are dominating [1], although
NDM-1 has been on the rise among this species recently [2].
VIM-producing K. pneumoniae (VPKP) has been associated with
hospital outbreaks in several countries [3–6], and has become
endemic in hospitals in certain countries such as Greece [5].
Worryingly, community-onset infections by VPKP have
recently been described [7], as well as isolates producing both
VIM and KPC-type carbapenemases [8].
The blaVIM-genes are located in class 1 integrons as gene
cassettes and have been identiﬁed on plasmids with differ-
ent replicon types [9], increasing the possibility of dissemi-
nation and linkage to other antibiotic resistance genes. As a
consequence, VPKP isolates often harbour other acquired
resistance genes (i.e. genes encoding aminoglycoside modify-
ing enzymes, 16S rRNA methylases, plasmid-mediated
quinolone resistance, trimethoprim resistance and other b-
lactamases). Molecular typing of VPKP isolates has shown
that in general the dissemination is multiclonal with some
clonal outbreaks. This is in contrast to what is observed
for KPC-producing K. pneumonia, where the majority of iso-
lates belong to multilocus sequence type (ST) 258 or
related STs [10].
In Scandinavia the emergence of carbapenemase-producing
Gram-negative bacteria has been mainly associated with the
importation of isolates [11,12]. Here we report the charac-
terization of VPKP isolates identiﬁed in Scandinavia from
2005 to 2008. (Part of this study was presented at the 20th
European Congress of Clinical Microbiology and Infectious
Diseases, Vienna, Austria.)
Materials and Methods
Bacterial isolates and clinical data
Eight clinical isolates of Klebsiella pneumoniae from the period
2005–2008 were included in this study (Table 1). Seven iso-
lates had been referred to the national reference centres in
Norway (n = 2) or Sweden (n = 5) based on non-susceptibil-
ity to carbapenems. One locally identiﬁed isolate from Den-
mark was also included. Clinical information was collected
retrospectively, including data on recent hospitalization
abroad. Bacterial identiﬁcation was performed using VITEK2
(bioMe´rieux, Marcy l’Etoile, France).
Antimicrobial susceptibility testing
Antimicrobial susceptibility testing was performed using Etest
according to the manufacturer’s instructions (bioMe´rieux)
and interpreted according to clinical breakpoints from the
European Committee for Antimicrobial Susceptibility Testing
(EUCAST, http://www.eucast.org/clinical_breakpoints).
Detection of resistance genes and sequencing of genetic
structure surrounding the VIM-genes
PCR was performed for the detection of MBL-genes (blaIMP,
blaVIM, blaSPM and blaGIM) [13], Klebsiella pneumoniae carbape-
nemase (KPC) [11], ESBL-genes (blaTEM, blaSHV and blaCTX-M)
[11], plasmid-mediated quinolone resistance genes (qnrA,
qnrB and qnrS) [14], and 16S rRNA methylases (armA, rmtA,
rmtB, rmtC, rmtD and npmA) [15,16]. Positive PCR products
were puriﬁed using Exo-SAP-IT according to the manufac-
turer’s instructions (GE Healthcare Bio-Sciences, Uppsala,
Sweden) and sequenced using BigDye 3.1 technology
(Applied Biosystems, Foster City, CA, USA).
The genetic structure harbouring the blaVIM genes was
identiﬁed by PCR ampliﬁcation of integrons using previously
described primers for intI1, qacED1 and IS26 [12,17] and
in-house designed primers. PCR products were puriﬁed from
agarose gels using a QIAquick gel extraction kit (QIAgen,
Hilden, Germany) and subsequently sequenced. Sequence
analysis and alignments were performed using Lasergene 8
(DNAStar, Madison, WI, USA) and compared with
sequences deposited in the GenBank database (http://
www.ncbi.nlm.nih.gov).
Multilocus sequence typing (MLST) and pulsed ﬁeld gel
electrophoresis (PFGE)
PFGE was performed using XbaI-digested genomic DNA
as described previously [11] and MLST was performed
TABLE 1. VIM-producing K. pneumoniae from Scandinavia
Isolate Year of isolation Specimen Place of isolation Hospitalization abroad, country MLST sequence type (ST)
O¨N-2211 2005 Sputum Stockholm, Sweden Greece ST147
T14789 2005 Urine A˚rhus, Denmark Greece ST147
AO-15200 2006 Wound secretion Stockholm, Sweden Greece ST147
U-60687 2006 Urine Stockholm, Sweden Greece ST36
K45-67 2007 Pus, catheter Oslo, Norway Turkey ST272
K46-62 2007 Urine Kongsvinger, Norway No ST273
HY-1491/7 2007 Faeces (screening) Stockholm, Sweden Greece ST147
B-22365 2008 Blood Stockholm, Sweden Greece ST383
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according to the K. pneumoniae MLST website (http://
www.pasteur.fr/recherche/genopole/PF8/mlst/Kpneumoniae.
html). eBURST (http://eburst.mlst.net) and minimum spanning
tree analysis (BioNumerics, Applied Maths, Sint-Martens-
Latem, Belgium) was used to analyse the MLST ﬁndings.
S1 nuclease digestion and in-gel hybridization
The genetic localization of blaVIM in seven out of eight iso-
lates was analysed by S1 nuclease treatment of total genomic
DNA followed by PFGE and in-gel hybridization with a
blaVIM-probe as previously described [12].
Transfer studies and PCR-based replicon typing (PBRT)
Conjugative transfer was performed by broth-mating at
donor:recipient ratios of 1:1 or 1:9 using the rifampicin resis-
tant Escherichia coli J53-2 as recipient. Transconjugants were
selected on Luria–Bertani (LB) agar supplemented with
100 mg/L rifampicin and 2–4 mg/L ceftazidime or 1 mg/L
ertapenem. Plasmids were isolated using a Nucelobond Xtra
Midi kit (Macherey-Nagel, Du¨ren, Germany) from conjuga-
tion negative isolates and used for transformation experi-
ments. Transformation was performed by electroporation of
plasmid DNA into electrocompetent E. coli TOP’10 cells
(Invitrogen, Carlsbad, CA, USA). Transformants were
selected on LB agar supplemented with 4 mg/L ceftazidime,
1 mg/L ertapenem or 100 mg/L ampicillin. PBRT was per-
formed using the protocol described by Carattoli et al. [18].
GenBank accession numbers
The nucleotide sequences for the integrons of strains K45-
67, K46-62, HY-1491/7 and U-60687 have been deposited in
GenBank with accession numbers FR748150, FR748151,
FR748152 and FR748153, respectively.
Results and Discussion
Molecular epidemiology
With one exception, all isolates were derived from patients
who had undergone recent medical treatment abroad either
in Greece (n = 6) or Turkey (n = 1), and were thus likely to
be imported cases (Table 1). Isolate K46-62 was recovered
from an 83-year-old female with no history of international
travel. A strong association with importation has also been
observed with the emergence of other carbapenemase-pro-
ducing Gram-negative clinical isolates in Scandinavia [11,12].
PFGE typing indicated a possible clonal relationship between
four isolates (O¨N-2211, T14789, AO-15200 and HY-1491/7)
with a Dice coefﬁcient between 72% and 86% (data not
shown). All four isolates were identiﬁed as MLST sequence
type (ST) 147 (Table 1). Isolate K46-62 was typed to ST273,
a single locus variant of ST147. K45-67, B-22365 and
U-60687 were typed to ST272, ST383 and ST36, respec-
tively. eBurst and minimum spanning tree analysis showed
that with the exception of ST272, which is a singleton in the
MLST database, the other STs are part of putative interna-
tional clonal complexes (data not shown). Both ST147 and
ST36 have previously been associated with CTX-M-15-pro-
ducing isolates from Hungary, [19] Spain, [20,21] and Tunisia,
[22] while ST383 has been associated with an isolate co-pro-
ducing VIM-4, KPC-2 and CMY-4 from Greece [8].
Antimicrobial susceptibility
All isolates expressed high-level resistance to penicillins,
cephalosporins and aztreonam, with the exception of one
isolate that was susceptible to aztreonam (Table 2). Carba-
penem MICs were variable, with two isolates categorized as
TABLE 2. Antimicrobial susceptibility of VIM-producing K. pneumoniae from Scandinavia and transconjugants (TC) and
transformants (TF)
Isolate
Antimicrobial susceptibility, MIC (mg/L)
AMC TZP CAZ FEP ATM MEM IPM ETP GEN TOB AMK CIP TIG COL
O¨N-2211 >256 >256 >256 128 32 32 32 8 >256 >256 >256 4 1 0.125
O¨N-2211-TC 32 >256 >256 128 32 1 4 1 >256 >256 >256 0.032 0.25 0.125
T14789 64 >256 >256 >256 8 >32 >32 >32 2 8 16 >32 2 0.125
T14789-TC 32 64 >256 32 1 0.5 2 0.25 1 4 8 0.032 0.25 0.125
AO-15200 32 >256 >256 128 256 32 32 8 2 16 16 >32 4 0.5
AO-15200-TF 64 >256 >256 64 0.125 1 4 0.5 1 8 8 0.008 0.5 0.125
U-60687 32 256 >256 256 256 >32 32 16 64 256 32 >32 0.5 0.125
U-60687-TF 64 >256 >256 16 16 1 8 2 1 8 8 0.008 0.5 0.125
K45-67 64 >256 >256 64 128 2 8 2 2 4 2 >32 1 0.5
K45-67-TC 32 128 >256 64 >256 1 4 0.5 2 4 1.5 1 0.25 0.125
K46-62 32 256 >256 64 0.25 8 8 8 2 4 2 1 0.5 0.25
K46-62-TC 64 >256 >256 128 0.125 2 4 1 4 8 2 2 0.25 0.125
HY-1491/7 32 >256 >256 >256 256 >32 16 >32 2 16 16 >32 1 0.25
HY-1491/7-TF 64 >256 >256 64 0.125 0.5 4 0.25 2 8 8 0.008 0.25 0.125
B-22365 32 >256 >256 64 256 2 2 4 64 32 16 >32 8 0.5
B-22365-TF 64 128 >256 16 0.125 0.5 4 0.25 1 4 8 0.006 0.25 0.125
E. coli J53-2 8 2 1 0.5 0.5 0.0625 0.5 0.016 0.5 1 2 0.032 0.25 0.25
E. coli TOP’10 4 2 1 0.5 0.125 0.032 0.5 0.016 0.5 1 2 0.032 0.25 0.125
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susceptible to meropenem. All isolates were intermediate
susceptible or resistant to ciproﬂoxacin and at least one ami-
noglycoside. Two isolates were resistant to tigecycline and
one was intermediate susceptible. Colistin was the only anti-
biotic that retained susceptibility in all the isolates. Several of
the transformants and transconjugants in this study were
fully susceptible to both meropenem and ertapenem
(Table 2), which have recently been suggested as the two
most sensitive antibiotics for detecting carbapenemases in
K. pneumoniae [23]. Low carbapenem MIC values for VIM-
producing clinical E. coli isolates have also been documented
[24], although such isolates have so far been described very
infrequently and in low numbers compared with VPKP [25].
According to these data, one explanation could be that the
MIC levels in MBL-positive E. coli are very low for the carba-
penems, making it very difﬁcult to identify these carbapenem-
ase producers unless epidemiological cut-off (ECOFF) values
from EUCAST are used [23].
Resistance determinants
blaVIM-1 was identiﬁed in six isolates, blaVIM-19 and a novel
variant, blaVIM-26, were detected in one isolate each
(Table 3). The novel variant, VIM-26 (isolate U-60687) har-
bours one amino acid mutation at position 224 (His224Leu,
BBL numbering scheme), compared with VIM-1. Residue 224
is located close to the active site of VIM enzymes and has
been shown to play a role in inhibitor interactions [26] and
suggested to affect the afﬁnity of substrates [27]. Leu224 has
previously been found in VIM-5 [28] and VIM-13 [29]. Both
VIM-5 and VIM-13 show reduced catalytic efﬁciency towards
cephalosporins with a bulky positively charged substituent
(e.g. ceftazidime and cefepime) [28,29]. However, mutagene-
sis studies on VIM-13 did not reveal a signiﬁcant effect of
Leu224 with respect to the susceptibility to ceftazidime and
cefepime [29]. Further, the VIM-26 transformant (U-60687-
TF, Tables 2 and 3) showed an elevated MIC of aztreonam
although it was negative for CTX-M, SHV and TEM ESBLs.
However, the presence of Leu224 in VIM-5 and VIM-13 did
not seem to have an effect on aztreonam [28,29]. Thus, the
elevated MIC is likely to be due to the presence of other
ESBLs. However, the signiﬁcance of the His224Leu mutation
in VIM-26 needs to be determined by kinetic experiments.
blaVIM-19, identiﬁed in isolate B-22365, has previously only
been identiﬁed in Algeria [30], France (patient transferred
from Algeria to France) [31] and Greece [32]. Characteriza-
tion of VIM-19 has suggested increased carbapenemase
activity compared with VIM-1 [31]. However, comparison of
B-22365 and the transformant with the other VPKP isolates
in this study did not reveal any increased MIC towards the
carbapenems.
Screening for other resistance genes in the isolates revealed
the presence of genes encoding extended-spectrum b-lacta-
mases (ESBLs) in ﬁve isolates (blaCTX-M-3, blaCTX-M-group 1,
blaSHV-5 and blaSHV-12, Table 3). BlaSHV-1 (n = 2), blaSHV-11
(n = 3) and blaTEM-1 (n = 3) were also detected. The 16S
rRNA methylase gene armA was identiﬁed in one isolate that
showed high-level aminoglycoside resistance and the plasmid-
mediated quinolone resistance determinant qnrS was detected
in two isolates. All isolates were negative for blaKPC.
Genetic context of blaVIM and plasmid analysis
The blaVIM gene was successfully transferred from all isolates
either by conjugation or transformation into recipient E. coli,
suggesting plasmid localization (Table 3). S1 nuclease PFGE
and in-gel hybridization of seven isolates (data not shown)
showed that blaVIM was located on plasmids ranging from
40 to 240 kb (Table 3). Co-transfer of blaVIM with other
resistance determinants such as blaCTX-M-3, blaCTX-M-gr.1,
TABLE 3. Genotypic characteristics of VIM-producing K. pneumoniae from Scandinavia and transconjugants (TC) and transfor-
mants (TF)
b-lactamases
16S rRNA
methylases/PMQR
Tn21-PCR and
Tn21-blaVIM linkage PCR Tn402-PCR VIM plasmid size PBRT
O¨N-2211 VIM-1, CTX-M-3, SHV-11, TEM-1 ArmA + (ND) – 60 kb IncN
O¨N-2211-TC VIM-1, CTX-M-3, TEM-1 ArmA – – ND IncN
T14789 VIM-1, SHV-11, TEM-1 – + (linked to blaVIM—1 kb) – 160 kb A/C
T14789-TC VIM-1 – – – ND –
AO-15200 VIM-1, SHV-5 – + (linked to blaVIM—1 kb) – 240 kb FIIAs
AO-15200-TF VIM-1 – – – ND –
U-60687 VIM-26, SHV-5 – + (linked to blaVIM—1 kb) – 40 kb A/C, FIIAs
U-60687-TF VIM-26 – – – ND A/C
K45-67 VIM-1, SHV-11, SHV-12 QnrS + (no linkage) – 50 kb IncN
K45-67-TC VIM-1, SHV-12 QnrS – – ND IncN
K46-62 VIM-1, SHV-1, SHV-12, TEM-1 QnrS + (no linkage) – 50 kb IncN
K46-62-TC VIM-1, SHV-12 QnrS – – ND IncN
HY-1491/7 VIM-1, SHV-11 – + (linked to blaVIM—1 kb) – 220 kb –
HY-1491/7-TF VIM-1 – – – ND –
B-22365 VIM-19, CTX-M-gr.1, SHV-1 – ND ND ND A/C
B-22365-TF VIM-19 – ND ND ND –
PBRT, PCR-based replicon typing; ND, not determined.
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blaSHV-12, blaTEM-1, qnrS and armA was observed. The
co-transfer of blaVIM-1, blaCTX-M-3 and armA as observed in
isolate O¨N-2211, resulting in resistance to all b-lactams and
aminoglycosides, is worrying as dissemination of such
multidrug resistance plasmids will have serious consequences
for treatment options. Linkage of blaVIM to Tn402 has been
previously reported in Scandinavia for Pseudomonas aerugin-
osa [12]; however, none of the K. pneumoniae integrons
possessed the tniA-C gene locus to the right-hand side of
the integron. Tn21-like transposons have been linked with
MBLs previously [33], and in the case of these isolates all
demonstrated Tn21 to the left-hand side of the class 1
integron, apart from isolates K45-67 and K46-62. These data
suggest that whilst the transposons are carried on different
plasmids that vary in size and type, the genetic structure of
Tn21 linked to blaVIM is largely conserved. Interestingly,
although we believe Tn21 to be functional in each of
these cases, chromosomal location of blaVIM could not be
demonstrated; however, the fact that this structure has
appeared on different plasmid scaffolds suggests recent
mobility.
Two different integron structures containing blaVIM
were identiﬁed in four isolates. In isolates U-60687 and
HY-1491/7, blaVIM-26 and blaVIM-1, respectively were located
in an integron similar to In-e541 [34], where blaVIM is located
as the ﬁrst gene cassette followed by aacA7, dhfrI, aadA1,
and the 3¢conserved segment (3¢CS) [intI1;blaVIM-1/-26;
aacA7;dhfrI;aadA1;3¢CS]. However, the aadA1 gene was trun-
cated in HY-1491/7, as observed in VIM-1-producing K. pneu-
moniae identiﬁed in France [6]. In-e541 has previously been
identiﬁed in different species, including Escherichia coli [34],
K. pneumoniae [35] and Acinetobacter baumannii. PCR-based
replicon typing (PBRT) [18] suggested that In-e541 was
located on an A/C plasmid in isolate U-60687 and on an
unknown replicon type in isolate HY-1491/7. This is in con-
trast to previous reports where In-e541 has been associated
with IncN plasmids [35].
In isolates K45-67 and K46-62, blaVIM-1 along with aac(6¢)-
Ib was located in an integron lacking the 3¢CS but instead
having an IS26 element in the 3¢end (intI1;blaVIM-1;aac(6¢)-
Ib;IS26). An identical structure has been identiﬁed in the
IncN plasmid pKOX105, shown to harbour blaVIM-1, qnrS1
and blaSHV-12 [36]. Interestingly, K45-67, K46-62 and the
respective transconjugants were positive for IncN, qnrS and
blaSHV-12, suggesting a similar plasmid. In the other isolates
PCR ampliﬁcation of the genetic context of blaVIM was unsuc-
cessful despite repeated attempts and the use of different
primer combinations.
In conclusion, the study shows that the emergence
of VPKP in Scandinavia is associated with importation of
international clones harbouring multiple resistance determi-
nants on plasmids, including plasmids with a broad-host
range, supporting further spread.
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